Researcher
Anke Maes
- Keywords:Medicine
Affiliations
- Clinical Biology (Department)
Member
From17 Apr 2023 → Today - Hematology (Research group)
Member
From1 Sep 2014 → Today - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2020 → 30 Sep 2022 - Basic (bio-) Medical Sciences (Department)
Member
From8 Apr 2019 → 31 Dec 2019 - Clinical sciences (Department)
Member
From8 Apr 2019 → 31 Dec 2019 - Clinical sciences (Department)
Member
From1 Jan 2019 → 31 Dec 2019 - Faculty of Medicine and Pharmacy (Faculty)
Member
From7 Aug 2015 → 18 Nov 2019 - Basic (bio-) Medical Sciences (Department)
Member
From1 Sep 2014 → 30 Sep 2022 - Faculty of Medicine and Pharmacy (Faculty)
Member
From14 Aug 2012 → 26 Jun 2014
Publications
1 - 10 of 11
- Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis(2023)
Authors: Arne Van der Vreken, Inge Oudaert, Gamze Ates, Sylvia Faict, Philip Vlummens, Hatice Satilmis, Rong Fan, Anke Maes, Ann Massie, Kim De Veirman, et al.
Pages: 112-123 - Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma(2023)
Authors: Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Eline Menu, Holly Evans, et al.
- Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism(2023)
Authors: Hatice Satilmis, Emma Verheye, Philip Vlummens, Inge Oudaert, Niels Vandewalle, Rong Fan, Jennifer M Knight, Nathan De Beule, Gamze Ates, Ann Massie, et al.
Pages: 69–80 - The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers(2022)
Authors: Rong Fan, Nathan De Beule, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman
- Aberrant DNA methylation in multiple myeloma(2022)
Authors: Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken, Elke De Bruyne
- System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance(2022)
Authors: Fang Wang, Inge Oudaert, Chenggong Tu, Anke Maes, Arne Van der Vreken, Philip Vlummens, Elke De Bruyne, Kim De Veirman, Yanmeng Wang, Rong Fan, et al.
- Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis(2022)
Authors: Inge Oudaert, Hatice Satilmis, Philip Vlummens, Wouter De Brouwer, Anke Maes, Dirk Hose, Elke De Bruyne, Bart Ghesquière, Karin Vanderkerken, Kim De Veirman, et al.
Pages: 45 - Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions(2022)
Authors: Jesús Bravo Melgar, Sofie Deschoemaeker, Geert Raes, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Damya Laoui, Kim De Veirman
- Kinome expression profiling to target new therapeutic avenues in multiple myeloma(2020)
Authors: Hugues de Boussac, Angélique Bruyer, Michel Jourdan, Anke Maes, Nicolas Robert, Claire Gourzones, Laure Vincent, Anja Seckinger, Guillaume Cartron, Dirk Hose, et al.
Pages: 784-795 - Exploring the therapeutic potential of targeting mitotic exit in combination with standard of care agents in high grade B cell malignancies.(2019)
Authors: Anke Maes, Karin Vanderkerken